September 27, 2022 02:32 PM EDTUpdated September 29, 02:37 PM

Genentech debuts next iteration of its Ocrevus MS campaign, targeting GenZ and Hispanic audiences

Beth Snyder Bulik

Senior Editor

In the newest campaign for multiple sclerosis brand Ocrevus from Roche’s Genentech, real patients celebrate “more progress” holding up the brand’s now-familiar two-finger peace sign …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genentech debuts next iteration of its Ocrevus MS campaign, targeting GenZ and Hispanic audiences

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Genen­tech de­buts next it­er­a­tion of its Ocre­vus MS cam­paign, tar­get­ing GenZ and His­pan­ic au­di­ences

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Genentech debuts next iteration of its Ocrevus MS campaign, targeting GenZ and Hispanic audiences

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival